The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently the biggest public health challenge to the biomedical community of the last century. Despite multiple public health measures,1, 2, 3 there remains an urgent need for pharmacologic therapies to treat infected patients, ...
Low-dose naltrexone is often used to treat chronic pain and autoimmune disorders. Now, for many struggling with debilitating post-COVID symptoms, it's one of the few treatments that works.
EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells Bita Jafary ,Mostafa Akbarzadeh-Khiavi &Khosro Adibkia Article 07 January 2025|Open Access Formulation development and evaluation, in silico PBPK modeling and ...
to swift success: Less than a year after the pandemic was declared, medical workers got their first vaccines. But as many people have refused the shots and stopped wearing masks, the virus still ragesand mutates. In 2022
Over the past month, price and quality complaints about anti-COVID drugs received by the 12315 consumer dispute resolution platform have increased by 528 percent from the previous month, and the number may continue to rise in the future, he added. ...
BEIJING, March 17 (Xinhua) -- A Chinese oral COVID-19 nucleoside drug, VV116, has commenced global trials in moderate and severe COVID-19 patients after having proven to be safe and well-tolerated in the tests of healthy people.
* China is implementing swift and concrete measures to accelerate drug development, production and supply in order to guarantee better treatment of COVID-19 cases, as the country adjusts its epidemic response policy. * Chinese drug researchers and developers have been racing against the clock to ...
As China continues to battle a surge in COVID-19 cases, pharmaceutical companies across the country have rushed to churn out ibuprofen, paracetamol and other fever medication."We are producing more than 10 times the number of ibuprofen injections compared to before December," said...
Weakened pathogenicity of the virus, a high vaccination rate and the accumulation of experience in prevention and control, have allowed China to optimize its COVID-19 response this winter. The current focus of China's epidemic response has shifted from preventing infections to beefing up treatment...
More importantly, the new drug compound was found to be effective against the Delta and Omicron variants in mouse models. The scientists compared the new drug to remdesivir, which was among the first COVID-19 treatments authorized in 2020. They highlighted that ATV006 has a simpler structure an...